

VIGIL MECHANISM POLICY

Contents

1. Introduction	03
2. Scope and Exclusion	03
3. Terms and References	03
4. Policy	04

1. Introduction

- 1.1 Reliance Life Sciences Private Limited ("RLS" or the "Company") is committed to conducting business with integrity, including in accordance with all applicable laws and regulations. The Company's expectations with respect to business ethics are contained in the Code of Conduct and Ethics (the "**Code of Conduct**").
- 1.2 Employees are required to report actual or suspected violations of applicable laws and regulations and the Code of Conduct, and the Company has an obligation to ensure that there is a procedure in place to enable the reporting of such violations.
- 1.3 This policy is framed pursuant to Section 177 of the Companies Act, 2013.

2. Scope and Exclusion

- 2.1 This Vigil Mechanism Policy (the "**Policy**") sets out the procedure to be followed when making a disclosure.
- 2.2 This Policy applies to all Employees, regardless of their location. Violations will result in appropriate disciplinary action. Please familiarize yourself with this Policy, and seek advice from the Vice President & Head, Clinical Research Services if any questions arise.

3. Terms and References

In this Policy, the following terms shall have the following meanings:

- 3.1 "**Code of Conduct**" means the Code of Business Conduct and Ethics.
- 3.2 "**Employee**" means any employee or director or officer of the Company.
- 3.3 "**Ethics & Compliance Task Force**" means the committee designated by the Board of Directors to process and investigate Protected Disclosures, comprising the Vice President & Head, Clinical Research Services, the Asst. Vice President, FC&A and the Asst. Vice President, HR L&D. The Vice President & Head, Clinical Research Services shall serve as the Chairperson of the Ethics & Compliance Task Force.

- 3.4 **"Nominated Director"** means a Director appointed by the Board of Directors in accordance with Section 177 of the Companies Act, 2013, who (in absence of Audit Committee) has responsibility for supervising the development and implementation of this Policy.
- 3.5 **"Protected Disclosure"** means the disclosure of a Reportable Matter in accordance with this Policy.
- 3.5 **"Reportable Matter"** means a genuine concern concerning actual or suspected:
- a. fraudulent practices, such as improperly tampering with the company's books and records, or theft of company property;
 - b. corruption, including bribery and money laundering;
 - c. breaches of the Code of Conduct;
 - d. breaches of applicable laws and regulations.

Please note that complaints concerning personal grievances, such as professional development issues or Employee compensation, are not Reportable Matters for purposes of this Policy.

- 3.5 **"Whistle-blower"** means any Employee who makes a Protected Disclosure under this Policy.

4. Policy

4.1 Responsibility to Report

Protected Disclosures are to be made whenever an Employee becomes aware of a Reportable Matter. The Protected Disclosure should be made promptly upon the Employee becoming aware of the Reportable Matter. Protected Disclosure should be made pursuant to the reporting mechanism described in Section 4.2 below.

The role of a Whistle-blower is limited to making a Protected Disclosure. A Whistle-blower should not engage in investigations concerning a Reportable Matter that is the subject of a Protected Disclosure. Neither should a Whistle-blower become involved in determining the appropriate corrective action that might follow from the submission of a Protected Disclosure.

4.2 Reporting Mechanism

- 4.2.1 The Company has established an Ethics & Compliance Task Force to process and investigate Protected Disclosures. The Ethics & Compliance Task Force operates under the supervision of the Nominated Director. Protected Disclosures are to be made to the Ethics & Compliance Task Force as follows:
- a. by **email** to ethics.taskforce@relbio.com; or
 - b. by **telephone** to Whistle-blower Hotline - +91 22 40678444; or
 - c. by **letter** addressed to the Ethics & Compliance Task Force, marked "Private and Confidential", and delivered to: The Chairman of the Ethics & Compliance Task Force, Reliance Life Sciences Private Limited, Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai – 400 701.
- 4.2.2 Moreover, in exceptional cases, Employees have a right to make Protected Disclosures directly to the Nominated Director as follows:
- a. by **email** to vigil.mechanism@relbio.com; or
 - b. by **letter** addressed to the Nominated Director, marked "Private and Confidential", and delivered to: Nominated Director, Vigil Mechanism, Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai – 400 701.
- 4.2.3 To enable the proper investigation of any Reportable Matter, a Protected Disclosure should include as much information as possible concerning the Reportable Matter. To the extent possible, the following information should be provided:
- a. the date of occurrence and nature of the Reportable Matter (for example, if the Reportable Matter concerns an alleged violation of the Code of Conduct, please refer to the provision of the Code of Conduct that is alleged to have been violated);
 - b. the names of the Employees to whom the Reportable Matter relates (for example, please provide the name of the business unit that is alleged to have violated the Code of Conduct);
 - c. the relevant factual background concerning the Reportable Matter (for example, if the Reportable Matter concerns a violation of the Code of Conduct, please include information about the circumstances and timing of the violation); and
 - d. the basis for the Protected Disclosure (for example, where knowledge of the alleged violation is based upon documents in the Whistle-blower's possession or control, please provide a copy of the pertinent documents).

4.2.4 To enable further investigation of Reportable Matters, Whistle-blowers are strongly encouraged to provide their name and contact details whenever they make a Protected Disclosure under this Policy. If a Whistle-blower does not provide his or her name and contact details when making a Protected Disclosure, the Company's ability to investigate the subject-matter of the Protected Disclosure may be limited by its inability to contact the Whistle-blower to obtain further information.

4.2.5 All Protected Disclosures are taken seriously and will be promptly investigated by the Company in accordance with the Guidance on Responding to Protected Disclosures.

4.3 Protection of Whistle-Blowers

4.3.1 If a Whistle-blower does provide his or her name when making a Protected Disclosure, the Company will treat as confidential the identity of the Whistle-blower and the fact that a Protected Disclosure has been made, except as otherwise required by law and to the extent possible while allowing an investigation to proceed.

4.3.2 A Whistle-blower may make a Protected Disclosure without fear of retaliation or intimidation. The Company prohibits its Employees from engaging in retaliation or intimidation directed against a Whistle-blower. Employees who engage in retaliation or intimidation in violation of this Policy will be subject to disciplinary action, which may include summary dismissal.

4.3.3 However, if a Whistle-blower has been found to have made a deliberately false Protected Disclosure, that Whistle-blower may be subject to disciplinary action, which may include summary dismissal.

4.4 Role of the Nominated Director

4.4.1 The Nominated Director is responsible for supervising the development and implementation of this Policy, including the work of the Ethics & Compliance Task Force. The Nominated Director shall periodically review this Policy to consider whether amendments are necessary, and, if so, it shall communicate any such amendments to all Employees as soon as possible after the said amendments are approved by the Board of Directors.

4.4.2 The Nominated Director shall receive reports from the Ethics & Compliance Task Force concerning the investigation and resolution of Protected Disclosures made pursuant to the Policy on a quarterly basis as per the guidelines given by the Board of Directors. In addition,

the Nominated Director shall have responsibility for co-ordinating the investigation of any serious Protected Disclosures concerning the alleged violation of laws or regulations that apply to the Company.

4.5 Conflict of Interest

Where a Protected Disclosure concerns any members of the Ethics & Compliance Task Force or the Nominated Director, that member of the Ethics & Compliance Task Force or the Nominated Director shall be prevented from acting in relation to that Protected Disclosure. In case of doubt, the Board of Directors shall be responsible for determining whether a member of the Ethics & Compliance Task Force or the Nominated Director must recuse himself or herself from acting in relation to a Protected Disclosure.

4.6 Questions

If you have any questions concerning this Policy, please contact:

Address	Jamila Joseph Vice President & Head – Clinical Research Services Reliance Life Sciences Private Limited Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai - 400 701
Email	jamila.joseph@ril.com
Telephone	+91 22 40678444

